Right now, that's none other than Eli Lilly (NYSE: LLY). However, others are looking to challenge its dominance. Recent ...

CEO Albert Bourla sits down with Yahoo Finance Executive Editor Brian Sozzi to talk about when consumers can expect to see ...

Pfizer enters the lucrative weight-loss drug market with a massive $10 billion Metsera acquisition, targeting a $150-200 ...

Health and Human Services Secretary Robert F. Kennedy, Jr. has come under fire for his views on vaccines. In an interview ...

At a price of up to $10 billion, Pfizer has claimed victory in its bidding war against Novo Nordisk to acquire Metsera. It's ...

"We can add value to what Seagen is bringing," Bourla said in a CNBC interview. "It's more or less a situation like when mRNA was in our hands. With our scale, with our capabilities, this is the same ...

Pfizer (PFE) managed to outbid competitor Novo Nordisk (NVO) to acquire Metsera (MTSR) in a deal valued at up to $10 billion. Pfizer stock is down by nearly 3% from this time a year ago. Robinhood ...

Pfizer (PFE) chairman and CEO, Albert Bourla, sits down with Yahoo Finance Executive Editor Brian Sozzi to discuss the future ...

Amid Novo Nordisk and Pfizer’s whiplash contest for obesity biotech Metsera, Novo’s CEO has, quite literally, told its rival to put its money where its mouth is. | Amid Novo Nordisk and Pfizer’s ...